Načítá se...
NF‐κB/NKILA signaling modulates the anti‐cancerous effects of EZH2 inhibition
A wealth of evidence supports the broad therapeutic potential of NF‐κB and EZH2 inhibitors as adjuvants for breast cancer treatment. We contribute to this knowledge by elucidating, for the first time, unique regulatory crosstalk between EZH2, NF‐κB and the NF‐κB interacting long non‐coding RNA (NKIL...
Uloženo v:
| Vydáno v: | J Cell Mol Med |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6714229/ https://ncbi.nlm.nih.gov/pubmed/31282094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14500 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|